China Medical System seals exclusive license to sell Bioflor diarrhea drug in China

China Medical System Holdings (AIM: CMSH) has signed an
exclusive license agreement with privately owned French
biopharmaceutical group Biocodex for the sale of Bioflor in China. The
agreement secures the exclusive rights to sell the probiotic
anti-diarrheal product for five years.

Under the terms of
the agreement, CMS has committed to purchase a minimum quantity of
Bioflor during the contract period. "We are pleased to be working with
Biocodex, our first French business partner, and with the addition of
Bioflor to our portfolio”, CMS chief executive, Lam Kong said, “This
agreement demonstrates our commitment to execute our growth strategy,
which is to in-license on an exclusive basis high quality products and
further expand our source of revenue."

Bioflor is a probiotic
anti-diarrheal product mainly used in the prevention and treatment of
diarrhea, a common gastroentrologic disorder found in adults and
children. According to Biocodex, the shared strategies of the
respective company’s and CMS’ strong sales network proves the best
option for the growth of the Bioflor product. “China represents one of
the top priorities in Biocodex's international development”, Biocodex
International director Nicolas Coudurier said.

Founded in
1953, Biocodex is an independent, family-owned French pharmaceutical
company specializing in gastroenterology, pain treatment, neurology and
psychiatry.